ItalyThe article reports on the significant increase in spending for anti-diabetic medications used to combat obesity in Italy, according to the AIFA report for 2025. The total expenditure reached €1.59 billion, marking a 34.9% rise compared to 2024. Semaglutide and tirzepatide saw particularly high growth, with consumption increasing by 85.7% and spending by 75.8% in the Fascia C category, which refers to private purchases. These drugs are now being used more frequently for weight loss and obesity treatment beyond their traditional diabetic applications. Public spending through the national health system (SSN) amounted to €430 million for semaglutide and €123.4 million for tirzepatide under specific guidelines. Private spending totaled €162.7 million for semaglutide and €225.5 million for tirzepatide. The report also notes that generic drugs accounted for 72.9% of spending and 88.1% of usage in conventional care settings, while branded equivalents made up 23.5% of spending and 32.1% of usage. Italy leads Europe in the use of biosimilar drugs, which are similar but not identical to branded drugs with expired patents. Regional disparities exist in medication costs, with southern regions,
Bias read (Center): The article presents factual data on pharmaceutical spending without overt ideological framing. It provides balanced information on both public and private expenditures, mentions regional disparities without taking a stance, and references official sources like AIFA without apparent bias. While the漲
